Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

Dolutegravir for younger children: results from the ODYSSEY trial

PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study

Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA

23 August 2019 vol 20 no 10

Fit for purpose: antiretroviral treatment optimisation July 2019

Fit for purpose 2019 – PDF

HTB 24 July 2019 online: first reports from IAS 2019

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

WHO recommends dolutegravir-based ART regimens for all

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

Fostemsavir: 96-week follow-up in people with multi-drug resistance

Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

24 July 2019 vol 20 no 9

Upcoming 10th IAS Conference on HIV Science (IAS 2019)

IAS 2019: late breaker highlights to look for

HTB 17 July 2019 online: IAS 2019, HIV pipeline, gene-cure mice…

HIV pipeline report 2019

Dolutegravir/lamivudine approved as dual HIV combination in EU

IAS–USA update of drug resistance mutations (2019)

HIV risk to partners of people in studies with a treatment interruption

Gene editing to eliminate HIV from mice: misleading and wrongly reported in media coverage

UNAIDS call on 48 countries and territories to remove all HIV-related travel restrictions

17 July 2019 vol 20 no 8

HTB 19 June 2019: vol 20 no 7 – PK Workshop, UK PrEP £17.50 a bottle

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs

Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine

Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants 

Infant dolutegravir exposure through placental and breastmilk transfer  

Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s

Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50

Activists challenge block to generic PrEP and current US price of TDF/FTC

FDA advisory committee votes favorably on use of pretomanid with bedaquiline and linezolid for drug-resistant TB

HIV criminalisation: report from HIV Justice Network

Venezuela: report on health and humanitarian emergency

19 June 2019 vol 20 no 7

HTB 20 May 2019: vol 20 no 6 – conference reports and PARTNER 2 published in The Lancet

13th INTEREST workshop 14–17 May 2019, Accra, Ghana

No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study

25th Annual BHIVA Conference (BHIVA 2019)

Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study

Management of testosterone deficiency in HIV positive people

Importance of including menopause and bone health in management of HIV positive women

Type 2 diabetes is often undermanaged in HIV positive people

Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths

Selected webcasts from BHIVA 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019

INSTI and weight gain: reports from CROI 2019

B/F/TAF suitable for children from six years of age

20 May 2019 vol 20 no 6

PARTNER 2 study published in the Lancet: global news coverage that ART stops HIV transmission

HTB 30 April 2019: vol 20 no 5 – BHIVA and CROI reports

25th Annual BHIVA Conference (BHIVA 2019)

BHIVA preconference: U=U and HIV and immigration detention

Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

Paediatric dolutegravir update

Post navigation